tradmap

PPCB Earnings Propanc Biopharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$1421 -$710 $0 2022 2023 2024 2025
EPS
Net income (annual)
-$59M -$29M $0 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-424% -28% 367% 0% 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$3836 -$1918 $0 Q3 '22 Q1 '23 Q4 '23 Q3 '24 Q1 '25 Q4 '25
EPS
Net income (quarterly)
-$54M -$27M $0 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25
Net income
Return on equity (quarterly)
-299% -137% 24% 0% Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25
ROE

Reported EPS history

1–16 of 16
Q3 20262026-03-31-0.952026-05-1410-Q
Q2 20262025-12-31-0.692026-02-1710-Q
Q1 20262025-09-30-0.392025-11-1410-Q
FY 20252025-06-30-14.852025-09-2910-K
Q3 20262025-03-31-38.622026-05-1410-Q
Q2 20262024-12-31-67.652026-02-1710-Q
Q1 20262024-09-30-35.972025-11-1410-Q
FY 20252024-06-30-1420.532025-09-2910-K
Q3 20252024-03-31-3164.412025-05-1510-Q
Q2 20252023-12-31-3835.552025-02-1410-Q
Q1 20252023-09-30-0.042024-11-1410-Q
FY 20242023-06-30-1.802024-09-3010-K
Q3 20242023-03-31-2.082024-05-1510-Q
Q2 20242022-12-31-2.102024-02-2010-Q
Q1 20242022-09-30-2.132023-11-1410-Q
FY 20232022-06-30-49.232023-09-2810-K

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.